ResearchIn-Press PreviewGeneticsHepatology
Open Access | 10.1172/jci.insight.171281
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by
Padula, A.
in:
JCI
|
PubMed
|
Google Scholar
|
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by
Spinelli, M.
in:
JCI
|
PubMed
|
Google Scholar
|
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by Nusco, E. in: JCI | PubMed | Google Scholar
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by Bujanda Cundin, X. in: JCI | PubMed | Google Scholar
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by Capolongo, F. in: JCI | PubMed | Google Scholar
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by Campione, S. in: JCI | PubMed | Google Scholar
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by Perna, C. in: JCI | PubMed | Google Scholar
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by Bastille, A. in: JCI | PubMed | Google Scholar
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by Ericson, M. in: JCI | PubMed | Google Scholar
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by Wang, C. in: JCI | PubMed | Google Scholar
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by
Zhang, S.
in:
JCI
|
PubMed
|
Google Scholar
|
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by Amoresano, A. in: JCI | PubMed | Google Scholar
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by Nacht, M. in: JCI | PubMed | Google Scholar
1Molecular Therapy, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
3Pathology Unit, Cardarelli Hospital, Naples, Italy
4In Vivo Pharmacology, LogicBio Therapeutics, Lexington, United States of America
Find articles by
Piccolo, P.
in:
JCI
|
PubMed
|
Google Scholar
|
Published September 14, 2023 - More info
Application of classic liver-directed gene replacement strategies is limited in genetic diseases characterized by liver injury due to hepatocyte proliferation resulting in decline of therapeutic transgene expression and potential genotoxic risk. Wilson disease (WD) is a life-threating autosomal disorder of copper homeostasis caused by pathogenic variants in copper transporter ATP7B and characterized by toxic copper accumulation, resulting in severe liver and brain diseases. Genome editing holds promise for the treatment of WD, nevertheless to rescue copper homeostasis ATP7B function must be restored in at least 25% of the hepatocytes, which surpasses by far genome editing correction rates.
We applied a liver-directed nuclease-free genome editing approach, based on adeno-associated viral vector (AAV) -mediated targeted integration of a promoterless mini-ATP7B cDNA into the Alb locus. Administration of AAV-Alb-mini-ATP7B in two WD mouse models resulted in extensive liver repopulation by genome edited hepatocytes holding a proliferative advantage over non-edited ones, and ameliorated liver injury and copper metabolism. Furthermore, combination of genome editing with a copper chelator currently used for WD treatment, achieved greater disease improvement compared to chelation therapy alone.
Nuclease-free genome editing provided therapeutic efficacy and may represent a safer and longer lasting alternative to classic gene replacement strategies for WD.